cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-2098Research ArticleПЕРЕДОВАЯ СТАТЬЯEDITORIALКардиоренальные взаимоотношения: современные представленияCardio-renal interrelation: modern viewКобалаваЖ. Д.KobalavaZh. D.

зав.кафедрой кардиологии и клинической фармакологии ФПК МР и зав.кафедрой пропедевтики внутренних болезней

ВиллевальдеС. В.VillewaldeS. V.

доцент кафедры пропедевтики внутренних болезней

villevaldes@mail.ruЕфремовцеваМ. А.EfremovtsevaM. A.

доцент кафедры пропедевтики внутренних болезней

МоисеевВ. С.MoiseevV. S.

зав.кафедрой факультетской терапии

Российский университет дружбы народов. МоскваRussian University of People’s Friendship. Moscow20102008201094411Copyright © Кобалава Ж.Д., Виллевальде С.В., Ефремовцева М.А., Моисеев В.С., 20102010Кобалава Ж.Д., Виллевальде С.В., Ефремовцева М.А., Моисеев В.С.Kobalava Z.D., Villewalde S.V., Efremovtseva M.A., Moiseev V.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/2098

Представлены определение и классификация кардиоренального синдрома (КРС) — патологического процесса, развивающегося в сердце или почках, при котором острая или хроническая дисфункция одного органа приводит к острой или хронической недостаточности другого. Обсуждаются патофизиологические механизмы, подходы к диагностике и лечению каждого из клинических вариантов КРС.

The paper discusses the definition and classification of cardio-renal syndrome (CRS) — a pathological process in heart or kidneys, characterised by acute or chronic dysfunction of one organ which results in acute or chronic failure of the other organ. The pathophysiological mechanisms, diagnostics, and treatment are described for each clinical variant of CRS.

кардиоренальный синдромкардиоренальные отношениянефропротекцияcardio-renal syndromecardio-renal interrelationnephroprotectionReferencesМоисеев В.С., Кобалава Ж.Д. Кардиоренальный синдром (почечный фактор и повышение риска сердечно-сосудистых заболеваний). Клин фармак тер 2002; 11(3): 16-8.Моисеев В.С., Кобалава Ж.Д. Кардиоренальный синдром (почечный фактор и повышение риска сердечно-сосудистых заболеваний). Клин фармак тер 2002; 11(3): 16-8.Мухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестник РАМН 2003; 11: 50-5.Мухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестник РАМН 2003; 11: 50-5.Мухин Н.А., Моисеев В.С., Кобалава Ж.Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер архив 2004; 6: 39-46.Мухин Н.А., Моисеев В.С., Кобалава Ж.Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер архив 2004; 6: 39-46.Schrier RW. Cardiorenal versus renocardiac syndrome: is there a difference? Nat Clin Pract Nephrol 2007; 3: 637.Schrier RW. Cardiorenal versus renocardiac syndrome: is there a difference? Nat Clin Pract Nephrol 2007; 3: 637.Ronco C. Cardiorenal and renocardiac syndromes: clinical disorders in search of a systematic definition. Int J Artif Organs 2008; 31: 1-2.Ronco C. Cardiorenal and renocardiac syndromes: clinical disorders in search of a systematic definition. Int J Artif Organs 2008; 31: 1-2.Liang KV, Williams AW, Greene EL, Redfield MM. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med 2008; 36: S75-88.Liang KV, Williams AW, Greene EL, Redfield MM. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med 2008; 36: S75-88.Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008; 34: 957-62.Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008; 34: 957-62.Bongartz LG, Cramer MJ, Doevendans PA, et al. The severe cardiorenal syndrome: ‘guyton revisited’. Eur Heart J 2005; 26: 11-7.Bongartz LG, Cramer MJ, Doevendans PA, et al. The severe cardiorenal syndrome: ‘guyton revisited’. Eur Heart J 2005; 26: 11-7.Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE). Am Heart J 2005; 149: 209-16.Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE). Am Heart J 2005; 149: 209-16.Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. JACC 2007; 50: 768-77.Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. JACC 2007; 50: 768-77.Jose P, Skali H, Anavekar N, et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol 2006; 17: 2886-91.Jose P, Skali H, Anavekar N, et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol 2006; 17: 2886-91.Goldberg A, Hammerman H, Petcherski S, et al. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction. Am Heart J 2005; 150: 330-7.Goldberg A, Hammerman H, Petcherski S, et al. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction. Am Heart J 2005; 150: 330-7.Roghi A, Savonitto S, Cavallini C, et al. Impact of acute renal failure following percutaneous coronary intervention on longterm mortality. J Cardiovasc Med 2008; 9: 375-81.Roghi A, Savonitto S, Cavallini C, et al. Impact of acute renal failure following percutaneous coronary intervention on longterm mortality. J Cardiovasc Med 2008; 9: 375-81.Lassnigg A, Schmid ER, Hiesmayr M, et al. Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: do we have to revise current definitions of acute renal failure? Crit Care Med 2008; 36: 1129-37.Lassnigg A, Schmid ER, Hiesmayr M, et al. Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: do we have to revise current definitions of acute renal failure? Crit Care Med 2008; 36: 1129-37.Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 2006; 1: 8-18.Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 2006; 1: 8-18.Han WK, Bonventre JV. Biologic markers for the early detection of acute kidney injury. Curr Opin Crit Care 2004; 10: 476-82.Han WK, Bonventre JV. Biologic markers for the early detection of acute kidney injury. Curr Opin Crit Care 2004; 10: 476-82.Ronco C. NGAL: an emerging biomarker of acute kidney injury. Int J Artif Organs 2008; 31: 199-200.Ronco C. NGAL: an emerging biomarker of acute kidney injury. Int J Artif Organs 2008; 31: 199-200.Herget-Rosenthal S, Marggraf G, Husing J, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004; 66: 1115-22.Herget-Rosenthal S, Marggraf G, Husing J, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004; 66: 1115-22.VandeVoorde RG, Katlman TI, Ma Q, et al. Serum NGAL and cystatin C as predictive biomarkers for acute kidney injury. J Am Soc Nephrol 2006; 17: 404A.VandeVoorde RG, Katlman TI, Ma Q, et al. Serum NGAL and cystatin C as predictive biomarkers for acute kidney injury. J Am Soc Nephrol 2006; 17: 404A.Han WK, Bailly V, Abichandani R, et al. Kidney injury molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int 2002; 62: 237-44.Han WK, Bailly V, Abichandani R, et al. Kidney injury molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int 2002; 62: 237-44.Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. JACC 2007; 13(49): 675-83.Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. JACC 2007; 13(49): 675-83.Tessone A, Gottlieb S, Barbash IM, et al. Underuse of standard care and outcome of patients with acute myocardial infarction and chronic renal insufficiency. Cardiology 2007; 108: 193-9.Tessone A, Gottlieb S, Barbash IM, et al. Underuse of standard care and outcome of patients with acute myocardial infarction and chronic renal insufficiency. Cardiology 2007; 108: 193-9.Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671-8.Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671-8.Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-9.Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-9.Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions — insights form the ESCAPE trial. JACC 2007; 51: 1268-74.Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions — insights form the ESCAPE trial. JACC 2007; 51: 1268-74.Jie KE, Verhaar MC, Cramer MJ, et al. Erythropoietin and the cardiorenal syndrome: Cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol 2006; 291: F932—44.Jie KE, Verhaar MC, Cramer MJ, et al. Erythropoietin and the cardiorenal syndrome: Cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol 2006; 291: F932—44.Palazzuoli A, Silverberg DS, Iovine F, et al. Effects of betaerythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007; 154: 645. e9-15.Palazzuoli A, Silverberg DS, Iovine F, et al. Effects of betaerythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007; 154: 645. e9-15.Uchino S, Bellomo R, Goldsmith D, et al. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med 2006; 34: 1913-7.Uchino S, Bellomo R, Goldsmith D, et al. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med 2006; 34: 1913-7.Bagshaw SM, George C, Dinu I, Bellomo R. A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. Nephrol Dial Transplant 2008; 23: 1203-10.Bagshaw SM, George C, Dinu I, Bellomo R. A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. Nephrol Dial Transplant 2008; 23: 1203-10.Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine and Biology, and the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). JACC 2006; 47: e1-192.Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine and Biology, and the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). JACC 2006; 47: e1-192.Sommerer C, Beimler J, Schwenger V, et al. Cardiac biomarkers and survival in haemodialysis patients. Eur J Clin Invest 2007; 37: 350-6.Sommerer C, Beimler J, Schwenger V, et al. Cardiac biomarkers and survival in haemodialysis patients. Eur J Clin Invest 2007; 37: 350-6.Austin WJ, Bhalla V, Hernandez-Arce I, et al. Correlation and prognostic utility of B-type natriuretic peptide and its aminoterminal fragment in patients with chronic kidney disease. Am J Clin Pathol 2006; 126: 506-12.Austin WJ, Bhalla V, Hernandez-Arce I, et al. Correlation and prognostic utility of B-type natriuretic peptide and its aminoterminal fragment in patients with chronic kidney disease. Am J Clin Pathol 2006; 126: 506-12.Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-59.Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-59.National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266.National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266.Мухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестник РАМН 2003; 11: 50-5.Мухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестник РАМН 2003; 11: 50-5.Мухин Н.А. Снижение скорости клубочковой фильтрации — общепопулярный маркер неблагоприятного прогноза. Тер архив 2007; 6: 5-10.Мухин Н.А. Снижение скорости клубочковой фильтрации — общепопулярный маркер неблагоприятного прогноза. Тер архив 2007; 6: 5-10.Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES I. Kidney Int 2002; 61: 1486-94.Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES I. Kidney Int 2002; 61: 1486-94.Sarnak MJ, Coronado BE, Greene T, et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002; 57: 327-5.Sarnak MJ, Coronado BE, Greene T, et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002; 57: 327-5.Gibson CM, Pinto DS, Murphy SA, et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. JACC 2003; 42: 1535-43.Gibson CM, Pinto DS, Murphy SA, et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. JACC 2003; 42: 1535-43.Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034-47.Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034-47.Levin A, Foley RN. Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis 2000; 36: S24-30.Levin A, Foley RN. Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis 2000; 36: S24-30.Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitorassociated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685-93.Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitorassociated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685-93.Roy P, Bouchard J, Amyot R, Madore F. Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients. Am J Kidney Dis 2006; 48: 645-51.Roy P, Bouchard J, Amyot R, Madore F. Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients. Am J Kidney Dis 2006; 48: 645-51.Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004; 351: 543-51.Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004; 351: 543-51.Ko DT, Juurlink DN, Mamdani MM, et al. Appropriateness of spironolactone prescribing in heart failure patients: a populationbased study. J Card Fail 2006; 12: 205-10.Ko DT, Juurlink DN, Mamdani MM, et al. Appropriateness of spironolactone prescribing in heart failure patients: a populationbased study. J Card Fail 2006; 12: 205-10.

The authors declare that there are no conflicts of interest present.